The calcium sensing receptor (CaSR) in the distal nephron decreases the propensity for calcium stones. Here we investigate if the apical CaSR in the proximal tubule also prevents stone formation acting via regulation of apical dicarboxylate and citrate transport. Urinary citrate, partially reabsorbed as a dicarboxylate in the proximal tubule lumen, inhibits stone formation by complexing calcium. We previously demonstrated a novel apical calcium-sensitive dicarboxylate transport system in OK proximal tubule cells. This calcium-sensitive process has the potential to modulate the amount of citrate available to complex increased urinary calcium. Using isotope labeled succinate uptake in OK cells along with various pharmacologic tools we examined whether the CaSR alters apical dicarboxylate transport and through which signal transduction pathways this occurs. Our results indicate that in the proximal tubule CaSR adjusts apical dicarboxylate transport, and does so via a CaSR → G q → PKC signaling pathway. Thus, the CaSR may decrease the propensity for stone formation via actions in both proximal and distal nephron segments.
Introduction
The calcium sensing receptor (CaSR) may play a role in decreasing the propensity for calcium stones. The CaSR is present in many tissues and has many roles. In the kidney, it is located throughout the nephron and has a multitude of functions varying with segment, polarity and cell type [1] [2] [3] [4] . Importantly, some of these functions in distal nephron segments are thought to prevent stone formation [5, 6] . Of note in the proximal tubule the CaSR is located on the apical membrane [7] and is found in the proximal tubule opossum kidney (OK) cell model [3, 8] . CaSR has been found to modulate both fluid reabsorption and H + secretion in the proximal tubule and gastric gland, perhaps via increases in intracellular calcium levels and ERK activity [9, 10] . The present study in OK cells explores a mechanism whereby CaSR in the proximal tubule may prevent stone formation acting via apical dicarboxylate (and citrate) transport.
Urinary citrate is the most important endogenous inhibitor of calcium nephrolithiasis. Citrate reabsorption in the upstream nephron determines urinary citrate which is available to complex calcium. The bulk of citrate transport is likely via the proximal tubule apical sodium dicarboxylate cotransporter (NaDC1) which reabsorbs dicarboxylic acids/Krebs cycle intermediates from the glomerular filtrate [11] [12] [13] [14] . In previous studies, we used the established OK cell model to study citrate and succinate transport and found inhibition by normal (1.2 mM) levels of extracellular Ca 2+ ([Ca 2+ ] o ) [15] [16] [17] [18] . (Succinate is used as a test dicarboxylate since its ionic state is not pH sensitive in the normal pH range.) In our prior studies a novel apical calcium-sensitive dicarboxylate transport process was found in OK cells; herein we examine the mechanism of calcium-sensitivity.
Although the initial purpose of the present studies was to determine whether CaSR regulates dicarboxylate/citrate transport, understanding the possible signal transduction mechanisms of this may be important in subsequent efforts to modulate citrate transport and hence stone formation via CaSR. The CaSR is known to couple variously to G q , G i and G s signaling proteins [19, 20] all of which are found in the proximal tubule [21, 22] . Our aim is to establish if calciumsensitivity of dicarboxylate transport is due to CaSR activation and what roles G q , G i and G s play. Signaling via G q activates phospholipase C (PLC) resulting in the release of [Ca 2+ ] i stores and activation of PKC [23] . G i and G s inhibit and activate adenylate cyclase (AC) respectively [19, 24] .
Methods
As previously described, OK cells were maintained in MEM containing 26 mM HCO 3 − supplemented with 10% FCS (Invitrogen), 25 mM HEPES, 11 mM l-glutamine and 100 IU/ml penicillin in a humidified atmosphere of 5% CO 2 at 37 °C [15] [16] [17] . Cell monolayers were grown on 24-well plates (Corning-Costar), with media changes every 2 days. After reaching confluence, cell monolayers were changed to serum-free media for a minimum of 24 h before experiments were performed. Dicarboxylate transport was measured by uptake of radiolabeled [
14 C]-succinate into cell monolayers. Just prior to uptake, cells were rinsed free of media and equilibrated for 2 min at 37 °C in buffer containing either normal (1.2 mM) or low (< 60 µM) [ Uptake was performed at 37 °C and started by adding 0.4 ml of uptake buffer with 0.626 mCi/ml [1,4- 14 C]-succinate (Moravek Biochemicals) to individual wells. Uptake buffer also contained [ 3 H] mannitol (Perkin Elmer) to determine the residual extracellular volume. After 3 min, buffer was removed and wells were rinsed 3X with ice cold 0.1 M MgCl 2 ; monolayers were lysed with 1 ml of 0.1 N NaOH and transferred to vials for liquid scintillation counting [15] [16] [17] [18] .
Uptake was calculated from measured 14 C radioactivity per well; appropriate windows and crossover calculations were used to distinguish between 3 H and 14 C. Uptake was further factored for residual extracellular volume, not removed by triplicate rinsing, calculated from the residual [ 3 H] mannitol. Because of variability in absolute transport rates, each experiment was performed in a paired fashion with both normal and low [Ca 2+ ] o solutions, with a minimum of four separate passages of OK cells for each experiment. Data are expressed as means ± SE. All statistical analysis was performed using one-way ANOVA. Statistical significance was defined as p < 0.05.
Unless otherwise stated all pharmacologicals were purchased through Sigma Aldrich (St. Louis, MO). ] o buffer Mg 2+ may be more likely to interfere. All other buffers and pharmacologicals were the same used in uptake experiments. Cells were treated with appropriate buffers and pharmacologicals, buffers were aspirated, 54 µl of 0.1 M HCl was added to each 1.9 cm 2 well, and incubated for 20 min at RT. Cells were scraped off, dissociated; lysates were centrifuged at 1000×g for 10 min followed by collection of supernatants. Standard curves and samples were prepared as per kit directions. Samples were diluted 2X and read at 412 nM. The pharmacological agents used in this study, listed in order of appearance are often used to investigate the signaling cascades involved in G-protein coupled receptor activation such as the proximal tubule apical CaSR shown in Fig. 1 . Spermine is a known orthosteric CaSR activator and was used in both transport and cell assay experiments [25, 26] . Thapsigargin (Thaps) is commonly used to increase intracellular Ca 2+ [27] . Phorbol 12-myristate 13-acetate (PMA) is a protein kinase C (PKC) activator [28, 29] . MDL-12,330A (MDL) is an adenylate cyclase (AC) inhibitor [30] . 8-Br-cAMP (8Br) is a cell membrane permeable form of cAMP [31] . The combination MDL + 8Br is used to examine the effects of increases of intracellular cAMP without the addition of effects from the upstream components of the signaling cascade. Pertussis toxin (PTX) is used to directly inhibit signaling by G i protein [32] . Forskolin is a known AC activator and is used to increase endogenous cAMP [30] Data are expressed as means ± SE. Each mean is derived from four individual experiments studied on 4 separate days. One-way ANOVA was used for statistical comparison in cAMP assays. Statistical significance was defined as p < 0.05.
Results
Our previous studies determined that normal levels (1.2 mM) of apical [Ca 2+ ] o inhibit apical dicarboxylate transport in OK cell monolayers [15] [16] [17] [8] . Since the CaSR is at the apical membrane of the proximal tubule, CaSR activation may be the basis of the apical calciumsensitive dicarboxylate transport we previously reported [15] [16] [17] [18] . If CaSR regulates apical dicarboxylate transport due to changes in luminal [Ca 2+ ] o levels, then apical addition of CaSR agonists may be used to test this hypothesis.
CaSR activation
To assess if CaSR activation is involved in alterations in apical dicarboxylate transport with changes in luminal Ca 2+ OK cell monolayers were treated with 1 mM spermine for 3 min during uptake (Table 1) . Spermine an orthosteric activator of CaSR [25, 26] ] o levels below 0.2 mM with activation threshold that can vary from 0.5 to 2 mM depending on cell type and levels of expression [8] . This additional level of inhibition may be an additive effect in which spermine, an orthosteric activator, increases CaSR activity beyond that which is observed in normal [Ca 2+ ] o .
G q signaling lowers dicarboxylate transport
Next we sought to determine which G-protein pathway the CaSR signals via in regulation of apical dicarboxylate/ citrate transport. As shown in Fig. 1 2+ and PKC activation ( Fig. 1 ) [33] . In HEK293 cells transfected with human CaSR, PLC activation followed by PKC activation is a G q -dependent and G i -independent process [34] . Thapsigargin is often used to increase [Ca 2+ ] i [27] . Thapsigargin ( Fig. 3 ) decreased dicarboxylate transport in both normal (100 ± 0.0 vs 73.5 ± 2.9% of control, p < 0.01) and low [Ca 2+ ] o (134 ± 7.2 vs 100 ± 8.2% of control, p < 0.01). This indicates that CaSR activation followed by increases in [Ca 2+ ] i via G q signaling results in decreased dicarboxylate transport in both normal and low [Ca 2+ ] o . Similar to the dicarboxylate transport processes we are currently studying, BGT1, the renal betaine/GABA transporter is also inhibited by [Ca 2+ ] o [35] . Figure 3 shows that thapsigargin treatment resulted in dicarboxylate transport inhibition in both normal and low [Ca 2+ ] o . This plus the spermine results ( Fig. 2) provides evidence that the CaSR via the G q pathway regulates dicarboxylate transport and G q signaling increases [Ca 2+ ] i possibly followed by PKC activation. Table 1 . Green arrows indicate stimulation, while red bars indicate inhibition by the pharmacological agents used in this study. Black arrows, up arrows, represent stimulation or increases and bars, perpendicular symbols, inhibition of some of the major components of G-protein coupled signaling cascade
PKC activation decreases dicarboxylate transport
The results described above show that both spermine and thapsigargin addition in low extracellular Ca 2+ mimics transport inhibition in normal [Ca 2+ ] o and thus links the CaSR to apical dicarboxylate transport regulation. G q signaling increases [Ca 2+ ] i followed by PKC activation; and PKC is known to regulate many cell membrane transporters [28, 29, [35] [36] [37] . PKC has also been shown to affect NaDC1 [38] . To investigate if PKC activation regulates apical dicarboxylate transport via G q , OK cell monolayers were pretreated with the PKC activator, 50 nM phorbol 12-myristate 13-acetate (PMA) for 30 min. Shown in Fig. 4 [19, 20, 24] .
If CaSR activation regulates dicarboxylate transport via G i signaling, the direct inhibition of G i would be expected to increase dicarboxylate transport in normal [Ca 2+ ] o . To investigate this we used the direct G i inhibitor pertussis toxin (PTX). OK cell monolayers were pretreated with PTX 100 ng/ml overnight. Shown in Fig. 5 , PTX had little effect on dicarboxylate transport in both normal (100 ± 0.0 vs 107 ± 1.9% of control, p = NS) and low [Ca 2+ ] o (174 ± 24 vs 178 ± 15% of control, p = NS).
G i activation
G i activation inhibits AC and hence cAMP production [19] . To determine if direct pharmacological inhibition of AC results in decreased dicarboxylate transport the AC inhibitor MDL-12, 330A (MDL) 50 nM for 30 min was applied to OK cell monolayers to mimic G i activation. If G i signaling regulates apical dicarboxylate transport via AC inhibition, MDL should inhibit apical dicarboxylate transport only in low [Ca 2+ ] o . Shown in Fig. 6 , MDL inhibited succinate transport in both normal (100 ± 0.00 vs 53.7 ± 7.4% of control, p < 0.01) and low [Ca 2+ ] o (146 ± 6.4 vs 88.7 ± 9.0% of control, p < 0.01).
These results with MDL ( Fig. 6 ) are unexpected when compared with those of PTX (Fig. 5) . MDL was used to directly inhibit AC (i.e., mimic G i ) which resulted in reduced dicarboxylate transport in both normal and low [Ca 2+ ] o . This decrease would be expected if CaSR regulation of dicarboxylate transport was via G i signaling. It is possible, however, MDL may decrease dicarboxylate transport in some way other than AC inhibition [39] [40] [41] . Some previous studies indicate MDL may have effects unrelated to AC inhibition such as blocking of L-type Ca 2+ channels, altering glycine transport and inhibiting phosphodiesterases [42] [43] [44] .
G s signaling
If G i signaling results in dicarboxylate transport regulation by reducing cAMP levels from inhibition of AC (consistent with MDL experiments), then increasing intracellular cAMP by addition of the membrane permeable 8-Br-cAMP (8Br) should result in increased dicarboxylate transport (Fig. 1) . Signaling via G s is known to result in AC activation which in turn increases intracellular cAMP [24] . In contrast to the MDL experiments, if CaSR activity results in decreased dicarboxylate transport in normal [Ca 2+ ] o due to G s activation of AC, increasing intracellular cAMP via 8Br would be expected to decrease dicarboxylate transport. ] o . Another way to investigate G i signaling is to directly inhibit AC by the addition of MDL-12,330A (MDL). OK cell monolayers were treated with 50 µM of MDL for 30 min before beginning transport measurements. MDL inhibited succinate transport in both normal (100 ± 0.00 vs 53.7 ± 7.4% of control, p < 0.01) and low [Ca 2+ ] o (146 ± 6.4 vs 88.7 ± 9.0% of control, p < 0.01). VC vehicle control. *p < 0.01. The MDL results differ from the results in Fig. 5 , where PTX had no effect on dicarboxylate transport; this discrepancy is addressed in the text However, addition of 8Br + MDL (Fig. 7) did not offset the effects of direct AC inhibition via MDL alone (Fig. 6 ) in normal (100 ± 0.0 vs 100 ± 5.1% of control) or low [Ca 2+ ] o (116 ± 9.2 vs 133 ± 8.7% of control) indicating that MDL may be acting via another mechanism [39] [40] [41] .
Increasing intracellular cAMP
Because of these varying results, further studies on G i signaling were needed to resolve the contrasting evidence with PTX and MDL. If CaSR activation results in decreased dicarboxylate transport via G i inhibition of AC, 8Br would be expected to reverse this inhibition and increase dicarboxylate transport due to rises in intracellular cAMP. However, If CaSR activation decreases transport via G s resulting in AC activation, 8Br should decrease dicarboxylate transport.
OK cells were pretreated with 100 µM 8Br for 30 min prior to uptake. 8Br (Fig. 8 ) had no effect on dicarboxylate transport in either normal (100 ± 0.00 vs 94.7 ± 1.7% of control, p = NS) or low [Ca 2+ ] o (154 ± 9.9 vs 131 ± 9.6% of control, p = NS). Thus, neither G i nor G s are involved in apical dicarboxylate transport regulation. Importantly, these results align with those of PTX (Fig. 5) , where inhibition of G i had no effect on dicarboxylate transport and thus supports actions of MDL are not likely the result of inhibiting AC, but some other mechanism not involved with G i [39] [40] [41] .
cAMP assays
Thus, far the CaSR-G q signaling studies indicate that CaSR inhibits apical dicarboxylate transport in normal [Ca 2+ ] o via G q -PKC signaling, but not via G i or G s signaling. To verify this, intracellular cAMP assays were performed. Endogenously G i is an inhibitor of AC and G s is an activator. If the CaSR signals via G i in OK cells AC inhibition would reduce cAMP levels; however, signaling via G s would result in AC activation and increased cAMP levels. Because the CaSR is known for ligand biased signaling (discussed below) it is important to examine the effects of [Ca 2+ ] o and spermine on endogenous cAMP levels to determine if there is a signaling bias.
Shown in Fig. 9 the level of [Ca 2+ ] o had no effect on intracellular cAMP levels (0.335 ± 0.103 vs 0.272 ± 0.095 pmol/ ml, p = NS). This further indicates that activation of the CaSR in OK cells does not signal via G i or G s . CaSR activator spermine also had little effect on cAMP levels in normal Fig. 7 Increasing intracellular cAMP does not offset the effects of AC inhibition on dicarboxylate transport. In this series of experiments MDL was used as a direct AC inhibitor to block increases in endogenously generated intracellular cAMP in all four groups of experiments. 8-Br-cAMP (8Br, 100 µM) is a cell membrane permeable form of cAMP [31] and was used to increase intracellular cAMP exogenously. Comparing bars 1 vs 2, increasing intracellular cAMP by the addition of 8Br did not overcome the direct inhibition of AC by MDL in normal [Ca 2+ ] o (100 ± 0.00 vs 100 ± 5.1% of control). Similar results were found in low [Ca 2+ ] o ; 8Br had no significant effect in the presence of MDL in low [Ca 2+ ] o (116 ± 9.2 vs 133 ± 8.7% of control) shown in bars 3 vs 4. And when 8Br concentrations were doubled to 200 µM, again there was no significant effect (116 ± 9.2 vs 130 ± 11.3% of control) shown in bars 3 vs 5. This provides further evidence that inhibition of dicarboxylate transport in both normal and low [Ca 2+ ] o (Fig. 6) is not via AC inhibition, indicating that MDL may be acting via another mechanism [39] [40] [41] 8 Increasing intracellular cAMP via 8-Br-cAMP has no effect on dicarboxylate transport. Intracellular cAMP in OK cell monolayers was increased by the addition of 100 µM 8-Br-cAMP (8Br) for 30 min before start of transport measurements. Raising intracellular cAMP had no effect on dicarboxylate transport in either normal (100 ± 0.00 vs 94.7 ± 1.7% of control, p = NS) or low (154 ± 9.9 vs 131 ± 9.6% of control, p = NS) [ ] o is not signaling via G i or G s . The CaSR activator spermine also had no effect on cAMP levels. This along with the PTX and 8Br studies is sufficient evidence to conclude that CaSR activation in OK cells does not result in G i or G s signaling.
The results with PTX and 8Br on transport, and the measurements of cAMP, indicate that changes in intracellular cAMP are not involved in transducing the CaSR signal involving apical dicarboxylate transport. MDL may be acting via effects unrelated to AC inhibition, explaining the sole discrepant results. MDL has been found to block certain Ca 2+ channels, alter glycine transport and inhibit non-cAMP phosphodiesterases [42] [43] [44] 
Discussion
Proximal tubule apical dicarboxylate transport is important from several perspectives, but for considerations here as the main regulator of citrate excretion, a potent inhibitor of nephrolithiasis. Citrate concentration in the urine is determined by proximal tubule reabsorption [45, 46] . Dicarboxylate transporters also reabsorb other filtered Krebs cycle intermediates and their downstream delivery (e.g., succinate and α-ketoglutarate) may be important in downstream receptor signaling which may also impact stone formation [47] .
In regards to citrate and stone prevention, teleologically increased urinary or luminal calcium should be matched by increased urinary or luminal citrate to prevent calcium precipitation with anions such as phosphate or oxalate, the complexes of which are not very soluble. Decreased reabsorption of citrate with increased luminal Ca 2+ would help achieve this. Our previous studies have established calcium-sensitive dicarboxylate transport at the apical membrane of the OK cell model of the proximal tubule. This calcium-sensitivity may play an important role in preventing stone formation by inhibiting citrate reabsorption in response to increased luminal Ca 2+ concentration [15] [16] [17] . Thus in the apical membrane of the proximal tubule CaSR activation may serve this function and regulate dicarboxylate transport [3, 7, 48] . Importantly (Fig. 2) The CaSR prevents Ca 2+ stone formation via segment specific functions throughout the nephron. For example, in the distal convoluted and connecting tubules the CaSR and the calcium-selective transient potential vanilloid-subtype 5 channel (TRPV5) co-localize at the luminal membrane and activation of the CaSR results in TRPV5-mediated Ca 2+ influx [5] . In the collecting duct, CaSR activation prevents nephrolithiasis by promoting H + -ATPase-mediated H + excretion and downregulation of Aquaporin 2. This results in urinary acidification and polyuria [6] . Clearly mechanisms in these other nephron segments prevent stone formation via CaSR activation. However, in the proximal tubule such mechanisms have not been described. The present results provide evidence that a mechanism in the proximal tubule may be that calcium activates CaSR which decreases citrate reabsorption, raising urinary citrate and decreasing the propensity for calcium stone formation.
The CaSR in the proximal tubule has been associated with the G q , G i or G s proteins. The G-protein through which it signals depends upon CaSR conformation [25, 49, 50] . Knowing the particular signaling pathway may be useful in the future to modulate citrate excretion. The CaSR has been extensively investigated including its propensity for ligand biased signaling [23, 33, 34, [51] [52] [53] . Traditionally there was a two-state model where G-protein coupled receptors (GPCRs) isomerize between inactive and active states [54, 55] . New concepts in GPCR signaling, termed ligand biased signaling, considers that various ligands may result in a variety of conformational changes to GPCRs that result in activation of different G-protein signaling pathways. For example the adenine A1 receptor can adopt agonist-specific conformations arising from small changes in ligand structure which result in differential activation of G i , G s and G q [56] The CaSR is known to couple to G q , G i and G s signaling proteins [19, 20] all of which are in the proximal tubule [21, 22] Though many GPCRs, including the CaSR, are known to activate more than one G-protein at a time, ligand biased signaling involves strong bias toward one pathway at the expense of others that may be activated under alternative conditions. Taken together, the results of spermine, thapsigargin and PMA experiments (Figs. 2, 3, 4) show that apical dicarboxylate transport inhibition in normal [Ca 2+ ] o occurs via the CaSR → G q → PKC pathway depicted in Fig. 1 . Results with PTX and 8Br on transport (Figs. 5, 7, 8) , and the measurements of cAMP (Fig. 9) , indicate that changes in intracellular cAMP via G s and G i are not likely involved in regulation of dicarboxylate transport by the CaSR.
In summary, in OK cells CaSR activation (even by normal [Ca 2+ ] o ) inhibits dicarboxylate transport via G q signaling. Our previous studies have consistently demonstrated calcium-sensitive dicarboxylate transport process in OK proximal tubule cells. Here we offer evidence that CaSR → G q → PKC signal transduction pathway regulates apical dicarboxylate transport. This pathway provides a mechanism whereby the proximal tubule apical CaSR prevents calcium precipitation by reducing apical dicarboxylate transport.
